This company is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Aerie Pharmaceuticals Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Belangrijke informatie
13.7%
Groei van de winst
18.2%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 7.3% |
| Inkomstengroei | 53.6% |
| Rendement op eigen vermogen | n/a |
| Nettomarge | -17.1% |
| Laatste winstupdate | 30 Sep 2022 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Aerie Pharmaceuticals geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 22 | 214 | -37 | 130 | 88 |
| 30 Jun 22 | 207 | -49 | 130 | 85 |
| 31 Mar 22 | 201 | -69 | 137 | 83 |
| 31 Dec 21 | 194 | -75 | 138 | 76 |
| 30 Sep 21 | 104 | -166 | 137 | 74 |
| 30 Jun 21 | 95 | -166 | 134 | 71 |
| 31 Mar 21 | 86 | -176 | 133 | 73 |
| 31 Dec 20 | 83 | -183 | 137 | 74 |
| 30 Sep 20 | 83 | -192 | 138 | 76 |
| 30 Jun 20 | 82 | -202 | 138 | 82 |
| 31 Mar 20 | 79 | -201 | 139 | 82 |
| 31 Dec 19 | 70 | -200 | 138 | 81 |
| 30 Sep 19 | 60 | -196 | 135 | 87 |
| 30 Jun 19 | 48 | -232 | 135 | 94 |
| 31 Mar 19 | 35 | -240 | 134 | 91 |
| 31 Dec 18 | 24 | -233 | 121 | 86 |
| 30 Sep 18 | 10 | -240 | 94 | 98 |
| 30 Jun 18 | 2 | -187 | 81 | 82 |
| 31 Mar 18 | 0 | -160 | 65 | 74 |
| 31 Dec 17 | 0 | -145 | 57 | 72 |
| 30 Sep 17 | 0 | -116 | 66 | 48 |
| 30 Jun 17 | 0 | -107 | 57 | 48 |
| 31 Mar 17 | 0 | -102 | 49 | 51 |
| 31 Dec 16 | 0 | -99 | 35 | 52 |
| 30 Sep 16 | 0 | -90 | 37 | 51 |
| 30 Jun 16 | 0 | -84 | 34 | 48 |
| 31 Mar 16 | 0 | -80 | 32 | 45 |
Kwaliteitswinsten: 0P0 is currently unprofitable.
Groeiende winstmarge: 0P0 is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 0P0 is unprofitable, but has reduced losses over the past 5 years at a rate of 13.7% per year.
Versnelling van de groei: Unable to compare 0P0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: 0P0 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (18.7%).
Rendement op eigen vermogen
Hoge ROE: 0P0's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.